TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05338151

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Brief Negotiated Interview (BNI)
Description: Brief Negotiated Interview (with referral and telephone booster) alone

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: BNI+facilitated provision of MAUD
Description: Brief Negotiated Interview (BNI)+ Medication for Alcohol Use Disorder (MAUD)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Negotiated Interview BNI+facilitated provision of MAUD+CBT4CBT
Description: Brief Negotiated Interview (BNI)+Medication for Alcohol Use Disorder (MAUD)+Computer Based Treatment for Cognitive Behavioral Treatment (CBT4CBT)
Study: NCT05325034

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Early Intervention
Description: Participant and clinician lipid score card to increase the likelihood of effecting guideline-directed change in lipid lowering therapy through two key actors - both the patient and their clinician(s).~The Score Card documents four key fields to be completed by the participant, study team and participant's regular clinician including 1) 'current' LDL-C level, 2) participant's level of adherence to lipid-lowering therapy using modified Voil's criteria, 3) lipid-lowering management decisions made at the clinician's appointment and 4) currently prescribed lipid-lowering therapies.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Early Intervention
Description: Participant and clinician lipid score card to increase the likelihood of effecting guideline-directed change in lipid lowering therapy through two key actors - both the patient and their clinician(s).~The Score Card documents four key fields to be completed by the participant, study team and participant's regular clinician including 1) 'current' LDL-C level, 2) participant's level of adherence to lipid-lowering therapy using modified Voil's criteria, 3) lipid-lowering management decisions made at the clinician's appointment and 4) currently prescribed lipid-lowering therapies.
Study: NCT05575141

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: incisional hernia repair
Description: Incisional hernia repair for the treatment of wide ventral incisional hernias.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: incisional hernia repair
Description: Incisional hernia repair for the treatment of wide ventral incisional hernias.
Study: NCT05259085

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN2050
Description: ALXN2050 (120 milligrams) will be administered orally twice daily on Days 1 through 3, with an additional dose (120 milligrams) administered orally on the morning of Day 4.
Study: NCT05896748

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabotegravir - Injectable Suspension (CAB LA)
Description: It is a sterile white to slightly pink suspension containing 200 mg/mL of CAB as free acid for administration by intramuscular (IM) injection. Each vial is for single-dose use containing a withdrawable volume of 2.0 mL, and does not require dilution prior to administration. CAB LA is composed of cabotegravir free acid, polysorbate 20, polyethylene glycol 3350, mannitol, and water for injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilpivirine - Injectable Suspension (RPV LA)
Description: It is a sterile white suspension containing 300 mg/mL of RPV as the free base. The route of administration is by intramuscular (IM) injection. Each vial contains a nominal fill of 2.0 mL, and does not require dilution prior to administration. RPV LA requires refrigeration and must be protected from light. RPV LA is composed of RPV free base, poloxamer 338, sodium dihydrogen phosphate monohydrate, citric acid monohydrate, glucose monohydrate, sodium hydroxide, water for injection.
Study: NCT06163651

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent-Child Assistance Program - One-Year Version
Description: Case managers work closely with parents over the course of one year, meeting them in their own homes when possible, to help them set goals and take advantage of available resources.
Study: NCT05633615

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Axicabtagene Ciloleucel
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood and tissue samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood and tissue samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood and tissue samples

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo collection of blood and tissue samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET-CT or CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET-CT or CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET-CT or CT

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo PET-CT or CT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lisocabtagene Maraleucel
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mosunetuzumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mosunetuzumab
Description: Given IV

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient Observation
Description: Undergo observation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polatuzumab Vedotin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polatuzumab Vedotin
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET-CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET-CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET-CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET-CT
Study: NCT06228703

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula device with flow setting at 40 L/min or higher
Description: Eligible participants will use the high-flow nasal cannula device (Airvo3 or HFT 750) with flow set at 40 L/min or higher
Study: NCT05633615

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Positron Emission Tomography
Description: Undergo PET-CT

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tisagenlecleucel
Description: Given IV
Study: NCT04704219

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 400 mg, every 6 weeks (Q6W) intravenous (IV) up to 18 infusions or up to progressive disease or discontinuation.
Study: NCT05111093

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ARC-IM Investigational System implantation
Description: Implantation of a stimulation lead on the low thoracic level of the spinal cord and implantation of a neurostimulator in the abdominal region.
Study: NCT05474846

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: Given by PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: Given by PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo for Melatonin
Description: Given by PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo for Melatonin
Description: Given by PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo for Melatonin
Description: Given by PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: Given by PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: Given by PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Description: Given by PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Description: Given by PO
Study: NCT06268860

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocatinlimab vial injection
Description: Vial solution for SC injection administered on Day 1

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Rocatinlimab prefilled syringe
Description: Prefilled syringe solution for SC injection administered on Day 1
Study: NCT06374264

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MR-C-014
Description: Use of device 3 times per week (for 30 minutes) for 8 weeks - for a total of 24 sessions.
Study: NCT05832723

Intervention type: DEVICE
Intervention: 650 nm low-level red-light
Description: Typically, children who uses the 650 nm low-level red-light will be recruited into this study. The use of any other myopia intervention is not restricted except for low concentrations of atropine. Because atropine will cause pupils dilated, the amount of light entering the eye can not be controlled, and red-light is a laser, to be safe, we need to take certain consideration of the amount of light-entering. Participants receive the 650 nm low-level red-light intervention not because they are enrolled in a study, they would receive the intervention in the same manner and intensity if they were not enrolled in the study.
Study: NCT06324955

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard/common language during induction
Description: The anesthesiologist taking care of the patient will use scripted common/standard language during the induction.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive language during induction
Description: The anesthesiologist taking care of the patient will use scripted positive language during the induction.
Study: NCT06549036

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Veteran Peer Decision Coaching Session for PSA Screening
Description: Veterans in the intervention arm will review the content of the mailed DA, including the values clarification exercise, with the Veteran PDC. Veteran PDC Counseling includes: 1) a structured interview with the patient that focuses on determining his understanding of his prostate cancer risk, his screening options, and his goals and values related to his decision making and 2) role playing exercises to improve SDM skills.
Study: NCT06629025

Intervention type: DIAGNOSTIC_TEST
Intervention: High-resolution impedance manometry
Description: High-resolution impedance manometry (HRIM) can calculate the bolus motion parameters and the ratio of complete esophageal transit
Study: NCT06630819

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 1.8 ml of 4% Articaine
Description: Buccal infiltration of 1.8 ml of 4% Articaine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3.6 ml of 4% Articaine
Description: Buccal infiltration of 3.6 ml of 4% Articaine.
Study: NCT04869657

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Coaches with Children's Hospital of Philadelphia (CHOP) Research Consultant Support
Description: Coaches employed by the school district will support the implementation of three evidence-based practices, while themselves being remotely supported by CHOP research consultants.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Coaches without CHOP Research Consultant Support
Description: Coaches employed by the school district will support the implementation of three evidence-based practices without any additional support from CHOP research consultants.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Coaches without CHOP Research Consultant Support
Description: Coaches employed by the school district will support the implementation of three evidence-based practices without any additional support from CHOP research consultants.
Study: NCT04704219

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Lenvatinib 20 mg, daily (QD), oral, until progressive disease or discontinuation.
Study: NCT05861089

Intervention type: DIAGNOSTIC_TEST
Intervention: end-tidal CO2 measurement
Description: Measurements will take place day before surgery, under resting conditions (while sitting in a quiet room with no disruptions) using the Capnography monitor from Nonin Medical (breath by breath data will be recorded and analyzed). Patients will be allowed to get used to the nasal cannula for the first two minutes. Mean end-tidal CO2 value will then be calculated from the following two minutes of spontaneous breathing.
Study: NCT06148753

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manuka Health Eternal Renewal Regenerating Face Serum with Royal Jelly and Bee Venom
Description: Face serum containing manuka honey, royal bee jelly, and bee venom.
Study: NCT06068153

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotorasib
Description: Sotorasib is administered at a dose of 960 mg (8x 120 mg) orally, once daily until progression or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Lenvatinib is administered at a dose of 20 mg orally (2x 10 mg), once daily until progression or unacceptable toxicity.
Study: NCT05785845

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Computed tomography-guided stereotactic adaptive radiotherapy
Description: Fractions will be delivered on consecutive business days.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ETHOS
Description: ETHOS is a unique ring-gantry CT-guided linear accelerator notable for having an on-board cone beam CT (CBCT) imaging unit with improved definition and resolution to enable target and organ-at-risk contouring. It also has a dedicated artificial intelligence treatment planning system to allow for online adaptive radiotherapy.
Study: NCT03934905

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sulforaphane
Description: The participants will be dosed, based on weight, in a double-blind fashion with identical appearing placebo or sulforaphane caplets in a daily dose for 12 weeks of: two caplets for individuals \<100 lb., four caplets for individuals 100-200 lb. and eight caplets for individuals \>200 lb. Avmacol or placebo will be prescribed by Dr. Awasthi and will be dispensed by local pharmacy or study coordinators at TTUHSC/UMC Lubbock. We will be doing pill counts to make sure that volunteers have used as directed. We will measure the Sulforaphane level in plasma by well-established method.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: The participants will be dosed, based on weight, in a double-blind fashion with identical appearing placebo or sulforaphane caplets in a daily dose for 12 weeks of: two caplets for individuals \<100 lb., four caplets for individuals 100-200 lb. and eight caplets for individuals \>200 lb. Avmacol or placebo will be prescribed by Dr. Awasthi and will be dispensed by local pharmacy or study coordinators at TTUHSC/UMC Lubbock. We will be doing pill counts to make sure that volunteers have used as directed. We will measure the Sulforaphane level in plasma by well-established method.
Study: NCT06517758

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iptacopan
Description: Hard gelatin capsule

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Hard gelatin capsule
Study: NCT06416670

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Skilled nursing facility care at home
Description: Skilled nursing facility care at home delivers a range of advanced rehabilitation services in patients' homes, enabling care at home despite requiring intensive rehabilitative care. Our approach blends personalized, high-level professional care with innovative technology applications to ensure adequate rehabilitation.
Study: NCT06681012

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral capsules are to be taken twice a day for 2 months (two capsules in the morning before breakfast and two capsules in the evening before dinner during the first 4 weeks of treatment; one capsule in the morning and one in the evening during the following 4 weeks of treatment).
Study: NCT06680648

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: addition of oxygeninsufflation via working channel of flexible scope
Description: addition of oxygeninsufflation via working channel of flexible scope in order to improve visibility when advancing the flexible scope

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: no-oxygen insufflation
Description: no-oxygen insufflation added to the flexible scope while advancing it
Study: NCT06327542

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group Acupuncture
Description: Acupuncture will be delivered in a group setting, in a common space with multiple reclining chairs. Acupuncture treatments will include a 10-15 minute diagnostic intake with the acupuncturist, followed by administration of acupuncture needles retained for 20-40 minutes. Acupuncture points will be selected based on a treatment manual developed for the study. All treatments will be administered using sterile, disposable, surgical stainless steel acupuncture needles.
Study: NCT06625086

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Convensional exercises
Description: Exercises will be provided to individuals in the Self-Guided Exercise group through a brochure.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supervised exercises
Description: Exercises will be administered to individuals with PFPS under the supervision of a physiotherapist.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Web based exercises
Description: The exercises will be administered to participants through a web-based application.
Study: NCT06327542

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group Acupuncture
Description: Acupuncture will be delivered in a group setting, in a common space with multiple reclining chairs. Acupuncture treatments will include a 10-15 minute diagnostic intake with the acupuncturist, followed by administration of acupuncture needles retained for 20-40 minutes. Acupuncture points will be selected based on a treatment manual developed for the study. All treatments will be administered using sterile, disposable, surgical stainless steel acupuncture needles.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integrative Group Medical Visits
Description: IGMV sessions will be weekly for 90-120 minutes in a group meeting space. Sessions will start with a check-in where participants can share their emotions, thoughts, hopes, and fears related to their health and pain and provide updates since the last session. Group sessions will be led by a primary care provider and a health educator and will include psychosocial support, tools for pain self-management, and psychoeducation for pain management. Invited experts will provide information on educational topics, including neurobiology of pain, medication safety, and connections between mood and pain, as well as participatory activities such as therapeutic movement or mindfulness practice.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integrative Group Medical Visits
Description: IGMV sessions will be weekly for 90-120 minutes in a group meeting space. Sessions will start with a check-in where participants can share their emotions, thoughts, hopes, and fears related to their health and pain and provide updates since the last session. Group sessions will be led by a primary care provider and a health educator and will include psychosocial support, tools for pain self-management, and psychoeducation for pain management. Invited experts will provide information on educational topics, including neurobiology of pain, medication safety, and connections between mood and pain, as well as participatory activities such as therapeutic movement or mindfulness practice.
Study: NCT05693844

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pan-T booster co-expressing MSLN CAR T cell
Description: Starting Dose: 1×10\^6 cells/kg
Study: NCT06683807

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hyperbaric bupivacaine 0.5% (2.5 mL) aspirated immediately after opening the bupivacaine ampule
Description: Parturients will receive spinal anesthesia for elective cesarean delivery with injection of 25 μg fentanyl plus 12.5 mg of hyperbaric bupivacaine 0.5% (2.5 mL) immediately after opening the bupivacaine ampule and directly after immediate aspiration with an unfiltered 3 ml syringe

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyperbaric bupivacaine 0.5% (2.5 mL) aspirated 5 minutes delayed after opening the bupivacaine ampule
Description: Parturients will receive spinal anesthesia for elective cesarean delivery with injection of 25 μg fentanyl plus 12.5 mg of hyperbaric bupivacaine 0.5% (2.5 mL) directly after 5 min' delayed aspiration from opening of the bupivacaine ampule with an unfiltered 3 ml syringe to allow glass particles to settle onto the bottom of the ampule
Study: NCT05693844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin-bound paclitaxel
Description: Administered intravenously at dose of 100-200mg/m2 on day -5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Administered intravenously at a total dose of 15-30mg/kg on day -3 and day -2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Administered intravenously at dose of 30mg/m2/d on day -3 and day -2
Study: NCT05436223

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human CD19Targeted T Cells Injection
Description: A single dose of predetermined level CAR-positive T cells will be infused.
Study: NCT06312553

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Remotely delivered Mindfulness-Based Diabetes Education with remote patient monitoring
Description: Remotely delivered Mindfulness-Based Diabetes Education with remote patient monitoring described in study arm

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Diabetes Self Management Education
Description: Standard Diabetes Self Management Education described in study arm
Study: NCT06005168

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefazolin for Injection
Description: 2 grams or 3 grams based on standard of care or morphomic-based decision